GLG News by Revlimid Prescribers: Hematologists (US)

President elect Obama will try , most probably unsuccessfully, to take on insurance companies in orfder to fulfill his election promises of "close to universal" health care. Generics will thrive, but Big Phrama , especially those with innovative products and biotech companies will continue to pr...

A recent study infers taht periods of increased rainfall could be linked to increase in number of children dioagnosed with autism. The causla l;ink of rainfall is unlikely, but most probably reflects other factors like children staying more indoors and thus watch more TV, get less sun exposure and...

Genetech's Avastin have shown modest increase in progresion free survival and overall survival in patients with gliobalstoma multiforme, the most common and most agressive malignant brain tumor With such data, Avastin is expected to join Temodar as chemotherapy agent approved for this tumor with...

The implication is that our new chief executive has "bigger fish to fry" than attaching drug costs??

"As part of the restructuring, the company plans to group its sales staff around specific treatment areas" including oncology, probably

Genetech is seeking FDA approval for use in the most malignant of brain tumors, Glioblastomas.

Sanofi's rapid acting insulin formulation got FDA approval for use in children 4 years and older with Type I insulin dependent diabetes. The drug has rapid action so it may replace lispro and older short acting  insulin preparations, if the price tag is not prohibitive.

Two Phase II trials show meanigful prolonged pFS in patients with iodine-refractory thyroid cancer who are treated with Sorafenib ( bayer/Onyx) The benefit needs to be confirmed in larger trials and need also to establish a favorable safety profile. Studies are needed for combination with other targeted...

Genesys terminated its studies of its cancer Vaccine for patients with refractory prostate cancer.  Cancer vaccine therapy remains limted to modest advantages in minimal residual diseases and in limted cases of melanoma and NHL

Genetic testing is the wave of the future to define targets for cancer therapy. EGFR, K-Ras and FLT-3 testing is just the beginning and affects the use of drugs such as Tarceva ( OSI-Genentech), Erbitux ( Imclone) , Veibitix ( Amgen) and Lasteurinib ( cephalon). The ultimate goal is to use more sophisticated...